Imunon, Inc. (IMNN) Stock Price & Analysis
Imunon, Inc. (IMNN) rose 0.50% to USD 2.02 as of June 10, 2026 at 06:57 UTC, according to Nexqual real-time market data.
IMNN last closed at USD 2.01; the session ranged USD 1.96–2.07 on volume of 33,379 shares. Market capitalization is $8.49M, with a 52-week range of USD 1.96–22.44 (NCM). Source: Nexqual, June 10, 2026 at 06:57 UTC.
Key Statistics (as of June 10, 2026 at 06:57 UTC)
| Price | USD 2.02 |
|---|---|
| Change | ▲ 0.50% (up) |
| Previous Close | USD 2.01 |
| Open | USD 2.05 |
| Day Range | USD 1.96 – 2.07 |
| 52-Week Range | USD 1.96 – 22.44 |
| Volume | 33,379 shares |
| Market Cap | $8.49M |
| Exchange | NCM |
Technical Analysis (IMNN)
Nexqual's technical model rates IMNN "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 06:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 19.73 (oversold) |
| vs SMA50 | Below (USD 2.67) |
| MACD | -0.18 (negative) |
Analyst Ratings (IMNN)
Wall Street analysts rate IMNN "Strong Buy" based on 5 analysts, with a mean price target of USD 17 (range USD 10–25), per Nexqual as of June 10, 2026 at 06:57 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 17 |
| High Target | USD 25 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (IMNN)
| EPS Estimate | USD -0.57 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.84 vs est -1.28 ▲ beat |
| 2025-12-31 | USD -1.3 vs est -1.82 ▲ beat |
| 2025-09-30 | USD -1.16 vs est -1.82 ▲ beat |
| 2025-06-30 | USD -1.87 vs est -4.34 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:57 UTC.
Financials & Fundamentals (IMNN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -768.20% |
| Debt / Equity | 27.14 |
| Current Ratio | 1.59 |
| Total Cash | $4.79M |
| Total Debt | $912,000 |
Source: Nexqual, June 10, 2026 at 06:57 UTC.
Financial Health Score (IMNN)
Nexqual rates Imunon, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 06:57 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $5M cash, no debt |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -768%, ROA -124.4% |
Ownership (IMNN)
| Insider Ownership | +1.47% |
|---|---|
| Institutional Ownership | +11.99% |
| Shares Outstanding | 4.20M |
| Float | 4.50M |
| Short % of Float | +1.38% |
Source: Nexqual, June 10, 2026 at 06:57 UTC.
Leadership (IMNN)
Imunon, Inc. is led by Stacy R. Lindborg (age 54), President, CEO & Director, per Nexqual as of June 10, 2026 at 06:57 UTC.
| President, CEO & Director | Stacy R. Lindborg (age 54) |
|---|---|
| Executive Chairman | Michael H. Tardugno (age 74) |
| Interim Chief Financial Officer | Jeffrey W. Church (age 68) |
| Senior Vice President of Strategic Operations | Kristin Longobardi |
Major Backers & Investors (IMNN)
Notable institutional backers of Imunon, Inc. include Armistice Capital, LLC, Riverview Capital Advisers, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 06:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 8.29% |
| Riverview Capital Advisers, LLC | 0.82% |
| Fidelity | 0.64% |
| HRT Financial LP | 0.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.87% |
| Geode Capital | 0.79% |
| BlackRock | 0.11% |
Source: Nexqual, June 10, 2026 at 06:57 UTC.
From Imunon, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States.
- The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
- It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial.
- In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.23 | ▼ 1.52% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.2 | ▲ 1.69% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
| SXTP | 60 Degrees Pharmaceuticals, Inc | USD 1.39 | ▼ 2.11% |
| TNON | Tenon Medical, Inc. | USD 0.62 | ▲ 2.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:57 UTC. This page is informational and not investment advice.